Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Capacity of Baseline Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index for Mirabegron Treatment Response in Women With Overactive Bladder: A Prospective Cohort Study

NCT07773532 is registered in ClinicalTrials.gov with Bagcilar Training and Research Hospital as lead sponsor.

NCT NCT07773532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07773532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Capacity of Baseline Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index for Mirabegron Treatment Response in Women With Overactive Bladder: A Prospective Cohort Study
Lead sponsor
Bagcilar Training and Research Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 1, 2027
Enrollment
115 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder (oab)